Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection

Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis, MASTERMIND Consortium
{"title":"Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection","authors":"Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis, MASTERMIND Consortium","doi":"10.1101/2024.09.01.24312905","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.01.24312905","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2 型糖尿病的精准医疗:瞄准 SGLT2 抑制剂治疗以保护肾脏
背景 目前的指南推荐钠-葡萄糖共转运体-2抑制剂(SGLT2i)为广大2型糖尿病(T2D)患者提供肾脏保护,但许多患者在关键的肾脏结果试验中并不具有代表性,其获益也不明确。我们的目标是确定这些人中哪些可能受益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Free fatty acids accelerate β-cell death in type 1 diabetes Detection of enterovirus RNA in pancreas and lymphoid tissues of organ donors with type 1 diabetes Sex and age differences in cardiovascular risk factors and lifestyle at the onset of diabetes mellitus: a cross-sectional study in Spanish Primary Health Care. Establishing a Core Outcome Set for Creatine Transporter Deficiency and Guanidinoacetate Methyltransferase Deficiency Primary aldosteronism results in a decline estimated glomerular filtration rate independent of blood pressure: evidence from a case-control and mendelian randomization study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1